Much progress has been made on blood-based biomarkers for neurological diseases, though challenges in this field should be addressed before they are applied into clinical use.
A study of the differences between healthy brains and those with Alzheimer’s disease has produced the largest dataset of its type ever.
In this review article from Biomarkers in Medicine, researchers explore the current application of blood-based markers to assess amyloid-β pathology.
Researchers have indicated that gingipain inhibitors may be used in treating periodontal disease and neurodegeneration in Alzheimer’s.
Researchers have identified a simple blood test that may be able to diagnose neurodegeneration before symptoms arise; this could lead to earlier diagnosis of Alzheimer’s disease.
An experimental drug being developed for the treatment of stroke may also prevent Alzheimer’s by preventing the build-up of toxic proteins.
An ‘exercise hormone’ has been reported to mediate the benefit of exercise in Alzheimer’s disease models by enhancing synaptic plasticity and memory.
A recent study has implicated that sticky proteins associated with neurodegenerative diseases could be transferred in mouse models.
Three novel radiopharmaceuticals have been evaluated for their potential to be utilized in PET imaging of tau proteins in humans. The results of the study have the potential to improve the way we diagnose and treat Alzheimer’s disease.
Research demonstrates that female mice display a unique pattern of fluctuation in sex hormones during the ovarian cycle that could be linked to cognitive impairments such as Alzheimer’s disease.
